In this report, the Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Geographically, this report split Asia-Pacific into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for these regions, from 2014 to 2025 (forecast), including
China
Japan
South Korea
Taiwan
India
Southeast Asia
Australia
Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs market competition by top manufacturers/players, with Benign Prostatic Hyperplasia (BPH) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Advaxis
Agennix
ANI Pharmaceuticals
BHR Pharma
Bristol-Myers Squibb
Boehringer Ingelheim
Dendreo
Endo Pharmaceuticals
On the basis of product, this report displays the sales volume (MT), revenue (Million USD), product price (USD/Kg), market share and growth rate of each type, primarily split into
Alpha-blocker
Phosphodiesterase type-5 inhibitors
5-alpha-Reductase inhibitors
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (MT), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for each application, includin
Clinical medicine
Scientific research
Others
Table of Contents
Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2019
1 Benign Prostatic Hyperplasia (BPH) Drugs Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Classification of Benign Prostatic Hyperplasia (BPH) Drugs by Product Category
1.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Comparison by Types (2014-2025)
1.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2018
1.2.3 Alpha-blocker
1.2.4 Phosphodiesterase type-5 inhibitors
1.2.5 5-alpha-Reductase inhibitors
1.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market by Application/End Users
1.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume) and Market Share Comparison by Applications (2014-2025)
1.3.2 Clinical medicine
1.3.3 Scientific research
1.3.4 Others
1.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market by Region
1.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Value) Comparison by Region (2014-2025)
1.4.2 China Status and Prospect (2014-2025)
1.4.3 Japan Status and Prospect (2014-2025)
1.4.4 South Korea Status and Prospect (2014-2025)
1.4.5 Taiwan Status and Prospect (2014-2025)
1.4.6 India Status and Prospect (2014-2025)
1.4.7 Southeast Asia Status and Prospect (2014-2025)
1.4.8 Australia Status and Prospect (2014-2025)
1.5 Asia-Pacific Market Size (Value and Volume) of Benign Prostatic Hyperplasia (BPH) Drugs (2014-2025)
1.5.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2014-2025)
1.5.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2025)
2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Competition by Players/Suppliers, Region, Type and Application
2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Players/Suppliers
2.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share of Key Players/Suppliers (2014-2019)
2.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Share by Players/Suppliers (2014-2019)
2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Type
2.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2014-2019)
2.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2014-2019)
2.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs (Volume) by Application
2.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Region
2.4.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Region (2014-2019)
2.4.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2014-2019)
3 China Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
3.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
3.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
3.1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
4 Japan Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
4.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
4.1.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
4.1.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
4.1.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
4.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
4.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
5 South Korea Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
5.1 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
5.1.1 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
5.1.2 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
5.1.3 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
5.2 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
5.3 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
6 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
6.1 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
6.1.1 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
6.1.2 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
6.1.3 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
6.2 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
6.3 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
7 India Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
7.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
7.1.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
7.1.2 India Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
7.1.3 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
7.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
7.3 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
8 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
8.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
8.1.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
8.1.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
8.1.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
8.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
8.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
9 Australia Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price)
9.1 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2014-2019)
9.1.1 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2014-2019)
9.1.2 Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2014-2019)
9.1.3 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Price Trend (2014-2019)
9.2 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Type
9.3 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share by Application
10 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Players/Suppliers Profiles and Sales Data
10.1 Astellas Pharma
10.1.1 Company Basic Information, Manufacturing Base and Competitors
10.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.1.2.1 Product A
10.1.2.2 Product B
10.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.1.4 Main Business/Business Overview
10.2 Eli Lilly
10.2.1 Company Basic Information, Manufacturing Base and Competitors
10.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.2.2.1 Product A
10.2.2.2 Product B
10.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.2.4 Main Business/Business Overview
10.3 GlaxoSmithKline
10.3.1 Company Basic Information, Manufacturing Base and Competitors
10.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.3.2.1 Product A
10.3.2.2 Product B
10.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.3.4 Main Business/Business Overview
10.4 Sanofi
10.4.1 Company Basic Information, Manufacturing Base and Competitors
10.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.4.2.1 Product A
10.4.2.2 Product B
10.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.4.4 Main Business/Business Overview
10.5 ADC Therapeutics
10.5.1 Company Basic Information, Manufacturing Base and Competitors
10.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.5.2.1 Product A
10.5.2.2 Product B
10.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.5.4 Main Business/Business Overview
10.6 Advaxis
10.6.1 Company Basic Information, Manufacturing Base and Competitors
10.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.6.2.1 Product A
10.6.2.2 Product B
10.6.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.6.4 Main Business/Business Overview
10.7 Agennix
10.7.1 Company Basic Information, Manufacturing Base and Competitors
10.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.7.2.1 Product A
10.7.2.2 Product B
10.7.3 Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.7.4 Main Business/Business Overview
10.8 ANI Pharmaceuticals
10.8.1 Company Basic Information, Manufacturing Base and Competitors
10.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.8.2.1 Product A
10.8.2.2 Product B
10.8.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.8.4 Main Business/Business Overview
10.9 BHR Pharma
10.9.1 Company Basic Information, Manufacturing Base and Competitors
10.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.9.2.1 Product A
10.9.2.2 Product B
10.9.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.9.4 Main Business/Business Overview
10.10 Bristol-Myers Squibb
10.10.1 Company Basic Information, Manufacturing Base and Competitors
10.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification
10.10.2.1 Product A
10.10.2.2 Product B
10.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2014-2019)
10.10.4 Main Business/Business Overview
10.11 Boehringer Ingelheim
10.12 Dendreo
10.13 Endo Pharmaceuticals
11 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
11.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
11.1.1 Key Raw Materials
11.1.2 Price Trend of Key Raw Materials
11.1.3 Key Suppliers of Raw Materials
11.1.4 Market Concentration Rate of Raw Materials
11.2 Proportion of Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
12 Industrial Chain, Sourcing Strategy and Downstream Buyers
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
12.2 Upstream Raw Materials Sourcing
12.3 Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2018
12.4 Downstream Buyers
13 Marketing Strategy Analysis, Distributors/Traders
13.1 Marketing Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Development Trend
13.2 Market Positioning
13.2.1 Pricing Strategy
13.2.2 Brand Strategy
13.2.3 Target Client
13.3 Distributors/Traders List
14 Market Effect Factors Analysis
14.1 Technology Progress/Risk
14.1.1 Substitutes Threat
14.1.2 Technology Progress in Related Industry
14.2 Consumer Needs/Customer Preference Change
14.3 Economic/Political Environmental Change
15 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2019-2025)
15.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue and Price Forecast (2019-2025)
15.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate Forecast (2019-2025)
15.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast (2019-2025)
15.1.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Price and Trend Forecast (2019-2025)
15.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue and Growth Rate Forecast by Region (2019-2025)
15.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate Forecast by Region (2019-2025)
15.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast by Region (2019-2025)
15.2.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.4 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.5 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.6 Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.7 India Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.8 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.2.9 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast (2019-2025)
15.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Price Forecast by Type (2019-2025)
15.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2019-2025)
15.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Forecast by Type (2019-2025)
15.3.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2019-2025)
15.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2019-2025)
16 Research Findings and Conclusion
17 Appendix
17.1 Methodology/Research Approach
17.1.1 Research Programs/Design
17.1.2 Market Size Estimation
17.1.3 Market Breakdown and Data Triangulation
17.2 Data Source
17.2.1 Secondary Sources
17.2.2 Primary Sources
17.3 Disclaimer